Find appropriate sickle cell disease (SCD) patients based on your practice
Please select the most common characteristics of the patients with SCD you treat to learn more
Currently taking hydroxyurea (HU) therapy
Age group
Maria is a patient who has similar characteristics to the HOPE trial population.
Not an actual patient
Maria
30-year-old Hispanic female with SCD genotype HbSS
She works at a bank and is a busy mother of 2 children
Relevant past medical history:
Received 2 blood transfusions in the past year
History of 2 vaso-occlusive crises (VOCs) in the past year
Current treatment of SCD:
Treated with HU, on maximum tolerated dose
Taking folic acid
Baseline lab workup:
Hb = 6.5 g/dL
Indirect bilirubin = 7.5 mg/dL
Reticulocytes = 12%
Jamie could be a potential patient because she has been treated with the max dose of HU and Oxbryta is indicated for patients as young as 4.
Not an actual patient
Jamie
12-year-old African American female with SCD genotype HbSS
She likes to play soccer
Relevant past medical history:
Presented with 1 vaso-occlusive crisis (VOC) in the past year
Current treatment of SCD:
Treated with HU, on maximum tolerated dose
Taking folic acid
Baseline lab workup:
Hb = 7.5 g/dL
Indirect bilirubin = 4.0 mg/dL
Reticulocytes = 9.0%
Henry has had >2 vaso-occlusive crises (VOCs) in the past year, like 58% of patients in the HOPE trial.
Not an actual patient
Henry
50-year-old African American male with SCD genotype HbSβ0 thalassemia
He worked as a consultant, traveling each week until 1 year ago
Relevant past medical history:
Cannot receive blood transfusions due to alloantibodies
History of 3 VOCs and 2 episodes of acute chest syndrome in the past year
Recently started an ACE inhibitor for diagnosis of proteinuria
Current treatment of SCD:
Discontinued HU therapy 5 years ago due to work lifestyle and inability to adhere to frequent lab monitoring
Baseline lab workup:
Hb = 7.0 g/dL
Indirect bilirubin = 6.5 mg/dL
Reticulocytes = 10%
Gabriel's parents have busy work schedules, making frequent medical appointments challenging. The safety profile observed in pediatric patients 12 to <17 years of age treated with Oxbryta was similar to that seen in adult patients.
Not an actual patient
Gabriel
Gabriel is a 14-year-old Hispanic male with SCD genotype HbSS
Both of Gabriel’s parents have busy work schedules, making it challenging to bring him in for frequent medical appointments
He often spends his free time playing video games and watching TV
Relevant past medical history:
Presented with 3 VOCs in the past year
Established microalbuminuria and complains of yellowing in his eyes
You are now leaving Global Blood Therapeutics’ site and moving to an external website independently operated and not managed by Global Blood Therapeutics. Global Blood Therapeutics assumes no responsibility for the site(s) you're visiting. If you do not wish to leave this site, click Cancel, or click OK to continue.
A message from Dr. Ted W. Love
President and CEO, Global Blood Therapeutics, Inc.
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
We are proud to participate in this important meeting and appreciate your interest in learning more about GBT and Oxbryta® (voxelotor) tablets. We at GBT share your passion and commitment to improving the lives of patients. Together, we can make a difference.
I encourage you to explore our website to learn more about Oxbryta.
NEJM does not hold itself responsible for statements made by any contributor. Statements or opinions expressed in NEJM reflect the views of the author(s) and not the official policy of the Massachusetts Medical Society unless so stated. NEJM reprints are not intended as the sole source of clinical information on this topic. Readers are advised to search the NEJM website at www.nejm.org and other medical sources for relevant clinical information on this topic. Reprints of articles published in NEJM are distributed only as free-standing educational material. They are not intended to endorse or promote any organization or its products or services.
By clicking OK, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of that site. If you do not wish to leave this site, click Cancel, or click OK to continue.
